Business Context and Reporting Period
This Form 8-K was filed by TRxADE HEALTH, Inc. (noting a discrepancy in the request metadata which listed "Scienture Holdings, Inc.") on September 7, 2022. The filing reports the entry into a material definitive agreement with White Lion Capital, LLC, a Nevada limited liability company, to establish a common stock purchase facility.
Key Financial Metrics and Agreement Terms
The filing details a Common Stock Purchase Agreement (the "White Lion Purchase Agreement") with the following financial parameters:
- Commitment Amount: White Lion has agreed to purchase up to $2,200,000 in aggregate gross purchase price of newly issued common stock, subject to Form S-3 eligibility.
- Purchase Price: Shares will be purchased at 90% of the lowest daily volume-weighted average price (VWAP) during a five-day valuation period following a notice.
- Transaction Limits: Individual purchase notices are capped at the lesser of $750,000 or 250% of the average daily trading volume over the preceding five business days.
- Commitment Shares: The Company must issue shares valued at $22,000 to White Lion upon termination if no purchase notices have been issued. These shares reduce the total Commitment Amount.
- Exchange Cap: The total number of shares issuable under the agreement is capped at 1,626,208 shares (approximately 19.99% of outstanding shares) unless shareholder approval is obtained.
- Term: The commitment period extends until the earlier of January 31, 2023, or the date all shares are sold.
The filing does not provide current revenue, profit, cash flow, or debt figures, as this is a current report regarding a specific agreement rather than a periodic financial statement.
Material Changes and Unusual Items
The primary material change is the establishment of the equity line of credit with White Lion Capital. Key unusual or specific items include:
- Amendments: The original agreement dated September 7, 2022, was amended twice on September 12, 2022, to correct certain provisions.
- Threshold Price Mechanism: If the stock price falls below 90% of the opening price on the Notice Date during the valuation period, the number of shares White Lion must purchase is reduced proportionately based on the time elapsed.
- Short Sale Restriction: White Lion agreed not to execute any short sales of the Company's stock from September 7, 2022, through the end of the commitment period.
- Use of Proceeds: Proceeds are designated for working capital and general corporate purposes with no financial covenants or restrictions on future financings.
Guidance, Outlook, and Risks
Outlook and Timing: The Company stated it is currently unable to estimate when, if ever, initial sales will be made under the agreement. Sales can only commence after the filing of a Prospectus Supplement and a Nasdaq listing notification.
Risks and Contingencies:
- Dilution: The agreement allows for the issuance of up to 19.99% of outstanding shares, which may dilute existing shareholders.
- Termination: The agreement automatically terminates if the Company commences a voluntary bankruptcy case or if a proceeding is commenced against it.
- Market Conditions: The Company may deliver purchase notices subject to market conditions and capital needs.
Investor Verification Checklist
- Verify the filing of the Prospectus Supplement to confirm the commencement of sales under the agreement.
- Monitor the stock price relative to the 90% VWAP pricing mechanism to assess potential dilution impact.
- Check for any shareholder approval filings if the Company intends to exceed the 19.99% Exchange Cap.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific legal covenants and indemnification provisions.
- Confirm whether the $22,000 Commitment Shares have been issued or if the obligation was waived by the issuance of a purchase notice.